Lonza agreed to sell its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3 billion (about US$3.0 billion). The deal is described as the final and most significant step in Lonza's strategic portfolio transformation, providing material proceeds and enabling the company to refocus on core operations and capital allocation decisions.
Lonza agreed to sell its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3 billion (about US$3.0 billion). The deal is described as the final and most significant step in Lonza's strategic portfolio transformation, providing material proceeds and enabling the company to refocus on core operations and capital allocation decisions.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.50
